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On 5th November C-EHRN held 
a day-long webinar of 
major sessions in lieu of the 5th European 
Harm Reduction Conference.
Part1
The first session was 2 hours long covering COVID-19 and the impact on harm reduction in 
Europe. Seven diverse perspectives were featured and each speaker provided a five-minute 
introduction followed by questions from a C-EHRN member.
 
 
WHO perspective: Nicole Simone, Unit lead for HIV and hepatitis at WHO EURO –    
Marinella Kloka, Praksis, Greece
EMCDDA perspective: Alexis Goosdeel, director – John Peter Kools, 
Trimbos Institute, NL
EuroNPUD perspective: Matt Southwell, director – Jose Queiroz, Apdes, Portugal
Policy maker perspective: Mariam Jashi, Georgian Member of Parliament
UNITE’s Chapter Chair from Eastern Europe & Central Asia) –  Ganna Dovbakh, EHRA
‘Nobody left Outside’ perspective: Prof Jeffrey Lazarus, ISGlobal –  
Dr. Rafaela Rigoni, C EHRN
COVID-19 and treatment of viral hepatitis: Prof. Dr. Mojca Maticic, University of  
Ljubljana – Christos Anastasiou, EuroNPUD, Greece
Global perspective: Ricardo Bapista, Unite  – Peter Sarosi, Drugreporter, Hungary
Moderator: 
Eberhard Schatz, C-EHRN




Nicole Simone gave an update on the status of the COVID vaccine. As is known, Europe 
has been hit hard by the coronavirus with nearly 300,000 deaths and 11 million cases as of 
November. 
When a safe and effective vaccine is found, WHO is working with COVAX global alliance 
(led by WHO, GAVI and CEPI) who will facilitate the equitable access and distribution of 
vaccines to protect people in all countries. Priority target populations are frontline health 
and care workers at high risk of infection, older adults and those with underlying conditions 
(including the vulnerable population of PWUD). Fair Allocation Framework aims to ensure 
that successful COVID-19 vaccines and treatments are shared equitably across countries. 
Nicole Simone Unit Lead for HIV 
and Hepatitis at WHO Europe






Aim of COVAX is to provide at least 2 billion vaccine doses worldwide by the end of 2021.
Lessons learned from harm reduction with HIV that it’s possible with a global emerging infec-
tious disease to have partnership between civil society, scientific community and govern-
ments to make a change by acting in a rapid manner to save lives. Other lessons learned 
from HIV is how to decentralize services such as rapid tests used by lay providers in the com-
munity for people to know their status as fast as possible. Also to think about who is at risk and 
who needs to be protected, both from a medical and a social standpoint. Most importantly, 
to think about vulnerable populations and equitable access as well as international solidarity 
and collaboration.
In addition, there are lessons from COVID-19 that apply to HIV & HCV. COVID-19 has given 
opportunities to do things that were recommended by key partners for a long time such as 
telemedicine, differentiated care, use of self-testing. The COVID-19 pandemic also gave an 
opportunity  to fast-track some innovations and governments and communities should con-




Alexis Goosdell discussed COVID-19 and the impact on harm reduction in the  
European Union. 
Alexis Goosdell Director,  
EMCDDA
Q&A: John Peter Kools Senior 




The disruption caused by COVID-19 and a strong drug market introduced new threats to 
health and security in Europe. Initially there were negative impacts on continuity of care 
and accessibility, then positive impact on innovation, digital innovation, flexibility and re-
newed relationship with the clients. Drug use patterns show an overall reduction in use of 
cocaine and MDMA and an  increase in cannabis, pills and alcohol. Retail drug markets 
were impacted in the beginning however there was a strong resurgence, particularly in the 
dark web.  Overall there is a concern for financial impact across many sectors, from eco-
nomic disruption to funding of harm reduction programs.
A question was posed as to whether problem drug use is increasing. Alexis Goosdell re-
sponded there is a new dataset from a web survey around 11,000 PWUD done by the EM-
CDDA. Overall there was a mixed image regarding cannabis use, some users stockpiled 
their drug. Many reported NPS on the market, around 40 and 50 new drugs on the market. 
Because of non-availability of opioids more people on OST, new means of enrollment were 
noted. Feedback from harm reduction is that there have been some positive changes and 
these should remain in the post-COVID-19.  Per Alexis Goosdell, harm reduction workers 




Mat Southwell described that COVID-19 has lead to a transformation in the delivery harm 
reduction, in particular OST. 
The widely-expected good behavior and absence of diversion has challenged 
fundamental assumptions in drug services. 
• The first assumption is that scaling up to full coverage of NSP is too big an ask. In Bath 
the secondary NSP was able to scale up to 100% coverage levels by using a peer-to-
peer system. 
• The second assumption is that THN is adequate to serve the population. EuroNPUD 
found that in the UK the peer-to-peer naloxone a superior service model for reaching 
non-service populations at scale. 
• Third assumption is that homeless drug users need OST to be stably housed. 
Mat Southwell,  
Director, EuroNPUD




With COVID requirement of abstinence waived, health benefits for drug users off the 
streets is substantial and helping people to engage with OST rather than make this a 
pre-condition. Lastly, the assumption that an annual survey of PWUD ticks the box on 
participation. The COVID-19 crisis has included widespread participation of PWUD for 
drug trends, utilization of drug services, and patterns of risk behaviors. 
Overall there are high levels of support for the new normal with more flexibility and less 
intrusion, increased focus on peer-support programs. 
The question was posed as to whether harm reduction professionals should be afraid of 
the PWUD engagement and the push for greater peer-to-peer services.  Mat responded 
that not at all, ideally it should be a collaboration between harm reduction services 
and PWUD. It is not about excluding the professional system but instead making space 
for the informal systems. The new European drugs agenda drafted by the European 
Commission was not so clear on social development and peer engagement. Ideally 
the focus on partnership and community participation is a key part of the strategy and 
that drug users are welcome to play a key role in participation of the public health and 
human rights of their community. In speaking about the shift to a new normal, the hope is 
that professionals and PWUD will be engaged. However there is a third actor, the dealer, 
does it make sense to engage them? Mat responded that it doesn’t make sense to 
necessarily victimize PWUD nor to see the dealers as bad actors, often there is a teaching 




Mariam Jashi reported on the situation in Eastern Europe and Central Asia. The pandemic 
has changed the basic routine of the national health systems and services. Other commu-
nicable or NCD’s have lost priority, there is concern with attention lost to TB (of the most 
priority infectious diseases in Eurasia). Reality is that the obstacles that harm reduction pro-
grams and policies faced in the pre-COVID era still remain and that policy priority of scale-
up of evidence-based interventions have been lost in the fight against COVID. There has 
been significant missed opportunity and time lost in advancing harm reduction.  Because 
of the pandemic harm reduction issues have not been identified as a “top priority”
However the region also has some good news. Most continued harm reduction programs 
despite strict quarantine. Take-home OST is now in the Eurasian region with the exception 
of Belarus, Azerbaijan & Kazakhstan. In the case in Georgia there were 11,000 beneficiaries 
taking home their OST and prevented COVID infections, only 5 cases reported among the 
11,000.  COVID also created better linkage between the NGO’s and the state. The pan-
demic is proving to be possible window for harm reduction, never before has government 
leaders listened so much to WHO etc. It has also been an opportunity to reiterate the im-
portance of the needs of the most vulnerable population. Ongoing advocacy is needed 
to be sure that harm reduction services that are so hardly won are not part of budgetary 
cuts. At the moment they are lacking significant quantitative and qualitative data from the 
pandemic response, civil society members can assist with documenting the situation on 
the ground. 
Mariam Jashi, 
Georgian Parliament Member & 
UNITE Chapter Chair for Eastern 
Europe and Central Asia




“Nobody left Outside” Perspective:
Professor Jeffrey Lazarus reported on the pandemic and marginalized populations. When a 
pandemic control communication strategy is drawn up, varying educational, cultural and 
language backgrounds must be taken into account so all population groups are engaged. 
Marginalized and vulnerable populations must not be forgotten. It is the responsibility of 
the system to reach marginalized populations and to reach those that are most difficult to 
reach (particularly in light of a potential vaccine).
In Spain overall harm reduction 
operating hours decreased in 
2020 compared to 2019. Top five 
issues in their Spain study were 
limited access to social workers to 
assist with social benefits, difficul-
ties with the police on the streets, 
limited access to drug checking 
services, and limited access to 
medical services. The “Nobody 
Left outside” Initiative has this 
important idea that communities 
are not hard to reach, health sys-
tems are hard to reach. Services 
had some difficulties during the 
pandemic to being open and 
accessible.
Prof Jeffrey Lazarus, 
ISGlobal (SP)






Professor Jeffery Lazarus was asked what lessons can we take from this pandemic in making 
services easier to reach rather than hard to reach, Closures of services took government 
by surprise, major role of NGO’s to engage with local, regional and national governments 
to ensure harm reduction services can stay open. Harm reduction services should be given 
exemptions and that harm reduction workers are allowed to leave their homes. The ques-
tion was posed how to keep meaningful positive changes after the pandemic, such as low-
er-barrier access to OST.  What is needed is to ensure we are tracking and demonstrating 
that it is indeed working and learning from where it’s not working.
Professor Lazarus was asked what else can we have in mind in terms of advocacy? His re-
sponse to think about how to keep harm reduction services open and fit-for-purpose during 
the pandemic.  In addition, how to build on the small successes we have had in terms of 
removing barriers to OST, such as lowering the threshold for prescriptions and take-homes. 
Also to think on  a potential role for harm reduction as providing medical information and 




COVID-19 & the Treatment:
Dr. Mojca Maticic discussed COVID-19 and viral hepatitis. In regards to COVID-19 and viral hep-
atitis treatment, chronic liver disease is a risk factor for severe COVID-19. What is being found is 
young patients with cirrhosis are dying at higher rates of COVID-19, mortality rate is thirty per-
cent for young people (age 20-30) with cirrhosis. Caring for patients with liver disease during the 
pandemic should involve greater personalization and flexibility,and treatment for HCV and HBV 
should continue according to guidelines.
Cirrhosis is hitting the community hard and there are still many barriers to treatment. In many re-
gions groups of people that are prisoners or migrants are still unable to get treatment.
 Dr. Maticic stressed the need to take advantage of COVID-19 period, to make the vulnerable 
populations more visible and utilize harm reduction centers as a point of service access for test-
ing. Harm reduction services are excellent locations as well for future COVID-19 vaccine roll-out. 
Drug use policy is a major barrier in elimination of hepatitis and the European Society for the Study 
of the Liver (EASL) supports drug decriminalization and integrated interventions such as HCV test-
ing, counseling and treatment. EASL recommends that “all barriers to the uptake of healthcare 
services by PWUD by removed by changing policy and removing discrimination that hinder ac-
cess.” 
Prof. Dr. Mojca Maticic,  
University of Ljublana





Ricardo Baptisa discussed the challenges and opportunities of the current crisis. This crisis 
has put a magnifying glass on the frailties and cracks in the system. The current model of 
health systems are not designed nor prepared to act with a public health perspective. In 
countries where harm reduction was not seen as a high priority before, now it’s completely 
forgotten. One the one side we are facing so many challenges but on the other side we 
are facing so many opportunities. This is an opportunity to put drug policy and harm reduc-
tion on the agenda and to ensure science is driving policy. The crisis exposed cracks in the 
system and social inequalities, and there is so much more to do than just giving out needles.
 
A question was posed for Ricardo Baptisa if there is a role for harm reduction advocacy 
to move beyond the needle-syringe basics to larger concepts in terms of advocating for 
things like universal basic income, housing crisis and other social services.  He noted that 
while 60% of the general population’s health depends on social determinants of health, 
during a pandemic that number rises rapidly (particularly in looking at the most under-
served populations). In Lisbon there was a noticeable rise in people needing meals during 
the pandemic, not just the most vulnerable but more and more middle-class families. It 
goes to show how grave and serious the consequences of this crisis will be. Better indica-
tors are needed that actually reflect upon the wellbeing of the people (not just the GDP 
of a country). The next question was posed on cannabis being on the agenda in a lot of 
countries, how can we be sure civil society has a voice in this? Is it really time to discuss this 
during the crisis in Europe? Ricardo noted a paper he published in 2018 looking at the ben-
efits and risks of cannabis and outcomes from a health, social, judicial and social perspec-
tive. He stated that publishing this paper changed his view to be an advocate for legaliza-
Ricardo Baptisa, 
President UNIT, Parliment Portugal





tion for personal use. While he does note there is a risk of having cannabis in the hands of 
multinationals, there is ongoing risk in the hands of black market and contamination with the 
products on the streets. Whatever legislation they come up with, they need to be sure they 
regulate it in a way that puts the people’s interests front and center. 
A brief Q&A session followed lead by Katrin Schiffer from C-EHRN. Questions were posed by 
speakers from INPUD. One speaker from Kazakhstan, asked for assistance from the WHO in 
bringing methadone to the country. Another asked the EMCDDA how can we ensure that 
harm reduction funding is not being cut down now? Alexis responded that EMCDDA is pre-
paring a joint statement for the european council in support of harm reduction funding. An-
other speaker asked Dr. Maticic about dolutegravir (medication for HIV) and whether COVID 
patients show improvements on this medication. Dr. Maticic responded that only dexameth-
asone and resdemevir have evidence for improving severe COVID.. Neither those drugs for 
HIV or any other drugs have shown benefit to treating or preventing COVID-19. Concern 
from speakers raised about future vaccine hoarding and allocation. Nicole Simone from 





Professor Nick Crofts introduced this special thematic series in the Harm 
Reduction journal, which seeks to examine new dimensions in harm re-
duction in 2020. The hope is to potentially broaden the harm reduction 
approach beyond drug use to other issues to which harm reduction is 
a successful approach. Another goal is to broaden the availability of 
the journal to marginalized peoples. 
Thematic Introduction:
Katrin Schiffer of C-EHRN introduced the specific themes of the spe-
cial edition of Harm Reduction, which includes diversity regarding the 
range of interventions, current challenges in policy and practice, the 
need for civil society involvement in monitoring and policy develop-
ment and the impact of COVID-19. This edition also features a histor-
ical perspective in which harm reduction has evolved in the past 40 
years showing that harm reduction works and has a positive impact 
on health and well-being. This historical perspective also shows the 
changes over time and the new and innovative interventions needed 
in the changing world. It also emphasizes the Importance of collecting 
and sharing evidence from the knowledge of practitioners and com-
munity members. 
The relationship between research, policy and practice is complex. 
In an ideal world, evidence should lead policy and practice. How-
ever policies are often not based on scientific evidence. In addition, 
policies are influenced by uncertainties and ambiguities. Finally, evi-
dence-based practice is not always feasible.  Scientific research often 









remains in the research community without involving the community on 
a practical level. Publications of articles is the desired outcome, it is less 
important how to translate into practice. Practitioners and community 
members feel like this type of research is detached from reality and 
doesn’t take into account the problems on the ground. 
The time has come to challenge the relationship between top-down 
practice paradigm to a more comprehensive participatory approach 
between communities, practitioners and researchers. This edition of the 
Harm Reduction journal seeks to do exactly this. 
For advocacy research is the key weapon, scientific data and publica-
tion is needed for speaking to the government and health specialists. 
Often the most difficult piece is to prove the efficiency of services, doc-
ument the impact of harm reduction and create this evidence. 
Published results are of practical experiences, the challenge is to fund 
the research itself. There is a need to advocate for funding sustainable 
services but also funding for sustainable research and data analysis. 
Community-led researchers are an important means of cooperation 
between scientific researchers and the community as well as usage of 
the data for advocacy.  
Commentary was provided by Alex Goosdeel, 
Raminta Stuikyte and Mat Southwell
Alexis Goosdeel shared a few ideas on challenges and lessons to be 
learned following the COVID-19 pandemic.
Lessons: 
• Harm reduction practitioners and services are an essential 
part of response to the pandemic. 
• Need to invest in innovation and digital skills. 
• Harm reduction programs are able to renew and reinvent 
themselves even in the most restricted settings and keep in 
touch with their most vulnerable clients. 
• Strong networks are needed to deliver a more integrated, 
holistic and person-centered response. 
Ghanna Dovbahk, 
Executive Director, EHRA





• PWUD are part of the solution, not just part of the prob-
lem. 
• There is an ongoing need to secure stable funding for 
harm reduction 
• There needs to be a push for more comprehensive and 
inclusive approach
• There is a need to reinvent harm reduction into a more 
holistic concept rather than siloed approach of just “nee-
dle exchange and methadone treatment”
• EMCDDA offers support and cooperation to harm reduc-
tion services to combinate research and practice.
Raminta made note of the major themes she found in this special 
edition
1. Stories of people left behind or the underserved 
2. Solutions that are well-known or about reinventing and 
understanding the changed world and changed needs. 
3. Solutions often require political will and handle the 
changing political world
4. Critical value of joining efforts 
5. Learning from east to west, from north to south, from his-
torical to current experiences
Mat Southwell emphasized the important interrelation of policy 
and research. He described his experience of launching a pilot 
program, not conducting any co-exisitng research and after the 
program got shut down losing all chance to prove the program 
was effective. 
This experience made him an advocate to demonstrate best 
practice and show impacts of harm reduction interventions. This 
evidence can be used to bring more resources and research be-
comes a critical advocacy tool. 
Raminta Stuikyte Senior Advisor, 






In regards to the history of harm reduction, harm reduction 
was born in the UK and the Netherlands. The first generation of 
harm reductionists were considered heretics. Needle exchange 
or methadone prescription was considered “heresy” from the 
medical organizations at the time. Pragmatism from colleagues 
is the only way to do this and COVID has helped us for this to 
become more of a reality. 
Nick Crofts reiterated the goal for Harm Reduction Journal to 
provide opportunities for marginalized voices to be heard and 
to get more diverse voices published.  
Ghanna Dovbahk closed the session with the reassurance that 
Harm Reduction Journal will do everything in their power to 
encourage community leaders and organizations to publish the 
data and to be connected to the science.
Alexis Goosdeel Director, 
EMCDDA
Prof Nick Crofts Editor-in-Chief, 
Harm Reduction Journal
Ghanna Dovbahk, 
Executive Director, EHRA
C CorrelationEuropeanHarm ReductionNetwork
